share_log

HC Wainwright & Co. Maintains Buy on Cartesian Therapeutics, Adjusts Price Target To $54

HC Wainwright & Co. Maintains Buy on Cartesian Therapeutics, Adjusts Price Target To $54

HC Wainwright & Co.维持对Cartesian Therapeutics的买入,将目标股价调整至54美元
Moomoo 24/7 ·  04/23 12:26

HC Wainwright & Co. analyst Mitchell Kapoor maintains Cartesian Therapeutics (NASDAQ:RNAC) with a Buy, adjusts target to $54 from $2.

HC Wainwright & Co. 分析师米切尔·卡普尔维持Cartesian Therapeutics(纳斯达克股票代码:RNAC)的买入,将目标从2美元调整至54美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发